Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

cancer."

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO's EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.

Contact

AVEO Pharmaceuticals, Inc.
JJ Owen, PhD, 617-299-5889
jjowen@aveopharma.com
or
Pure Communications
Adriana Jenkins, 617-744-1713


'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting

Post Your Comments:
(Date:11/6/2009)... -- Trius Therapeutics, Inc. announced today that ...with the U.S. Securities and Exchange Commission (...g of shares of its common stock. All shares of the...ffered by the Company. ,, Credit Suisse Securit...er, Piper Jaffray & Co. is acting as co-lead m...
(Date:11/6/2009)...swire/ -- Kaiser Foundation Health Plan, Inc., Kai...diaries reported today a combined total operating ...tember 30, 2009, compared to $10.2 billion in the ...e third quarter was $336 million, compared to $307...n-operating income was $233 million in the third q...
(Date:11/6/2009)...wire-FirstCall/ -- Roper Industries, Inc. (NYSE:...itive agreement to acquire Verathon, Inc., a leadi...erathon Board of Directors has approved the transa...latory approvals and closing conditions, including...sing to be completed in early December. ,, Hea...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Avoiding Hysterectomy 3A Major Interventional Radiology E collection Info Available 51668 1Avoiding Hysterectomy 3A Major Interventional Radiology E collection Info Available 51668 2Avoiding Hysterectomy 3A Major Interventional Radiology E collection Info Available 51668 3Avoiding Hysterectomy 3A Major Interventional Radiology E collection Info Available 51668 4UK Court of Appeal Rules in Smith 26 Nephews Favour 51666 1UK Court of Appeal Rules in Smith 26 Nephews Favour 51666 2UK Court of Appeal Rules in Smith 26 Nephews Favour 51666 3Improving Transfusion Safety 3A Fenwal Verax Biomedical Sign Agreement for Rapid Point of Care Bacteria Test 13025 1Improving Transfusion Safety 3A Fenwal Verax Biomedical Sign Agreement for Rapid Point of Care Bacteria Test 13025 2Improving Transfusion Safety 3A Fenwal Verax Biomedical Sign Agreement for Rapid Point of Care Bacteria Test 13025 3
...g Regimen, SEATTLE, May 7 Trubion Pharmaceutical...artner, Wyeth Pharmaceuticals, a,division of Wyeth...e next,Phase 2b clinical trial of TRU-015 in patie...on with Trubion, Wyeth Pharmaceuticals is developi...ts., The randomized, parallel, double-blind, plac...
...aq: SHPGY), the global specialty biopharmaceutical... analysis that was conducted to examine,treatment ...nsdermal,system) between boys and girls aged 6 to ...rder (ADHD). The findings from the analysis reaffi...le and effectively controlled,ADHD symptoms in bot...
Other Medicine Technology:Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7
(Date:11/8/2009)... Swift Passage of H.R. 3961 to Secure the Stabilit...SNewswire/ -- Statement Attributable to: J. James ...ion. ,, (Logo: http://www.newscom.com/cgi-bin...e passage of the House health reform bill, which w...d physicians and calls for swift passage of H.R. 3...
(Date:11/8/2009)... Calif., Nov. 8 March o...bies luncheon to recognize prominent individuals w... who are role models for March of Dimes commitment...March of Dimes November Prematurity Awareness Mont...ged to join the fight for preemies! ,, (Photo: ...
(Date:11/7/2009)... T. Coleman (CT), David A. Cook (GA), Louis J. Goo...LA) Honored ,, CHICAGO, Nov. 7 /PRNewswire-USN... today presented five medical society executive le...ibutions to the goals and ideals of the medical pr...emi-annual policy making meeting in Houston. ,...
(Date:11/7/2009)..., Nov. 7 The U.S. bisho...entatives to vote for the Stupak-Ellsworth Amendme...lsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Ame...bortion funding and conscience protections in the ...," they said. ,, The letter was signed by Cardi...
(Date:11/7/2009)...k to stem a growing problem across the U.S. , ...half of students at four-year colleges do it regul...nking -- downing five or more alcoholic drinks at ...alcohol as a drug," said Jenny Hwang, associate de...er at Stony Brook University on Long Island, N.Y. ...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3
...ide,Health Properties, Inc. (NYSE: NHP ) announce...r Vice President and Senior Investment Officer. "D... the last several years as,evidenced by our strong...his vast experience and relationships in,healthcar...
...for at least a year or two, , , FRIDAY, Ma...help people with type 1 diabetes live insulin-free... longer-term improved metabolic control even after... Miller School of Medicine found that diabetics wh...
...PG Aquarium for May 28, PITTSBURGH, May 16 UPMC ..., is the Pennsylvania state sponsor for the 15th a...has as its theme, "Fitness ...,A Lifetime Investme...nia. The theme of each event is "Fitness ... A Lif...
... - Earlier this morning, Atomic,Energy of Canada L...lopment,of the MAPLE reactors at Chalk River, but ...edical isotopes., MDS Inc., a leading provider of...ments. MDS Nordion, a business unit,of MDS, is a l...
...unch strategies,allow best-in-class pharmaceutical...s. To secure "share of voice" for a new product, l...s to support business needs and,ensure a successfu...ices for Winning Product Launch Successes" is an,i...
...idents to Eat Right, Move More and ...e last decade can be defined by the,ups and downs ...out of,fashion like shoulder pads and hemlines. Ye...mpaign crossing the country, the Campaign for Heal...
Other Medicine News:Health News:David M. Boitano Promoted to Senior Vice President 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3Health News:UPMC for Life is Pennsylvania Sponsor for National Senior Health & Fitness Day 2Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: